If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide [rDNA origin] injection): Half Life
Forteo® is quickly absorbed from the injection site, has a half-life of approximately 1 hour, and is undetectable in the blood within 3 hours.
Teriparatide is quickly absorbed from the injection site, has a half-life of approximately 1 hour, and is undetectable in the blood within 3 hours.1
Absorption
Teriparatide is rapidly and extensively absorbed following subcutaneous injection, with a maximum serum concentration at approximately 30 minutes.1,2
Distribution
The half-life of teriparatide in serum is approximately 1 hour when administered by subcutaneous injection.1,2
Elimination
Systemic clearance of teriparatide is approximately 62 L/hr in women and 94 L/hr in men, which exceeds the rate of normal liver plasma flow, consistent with both hepatic and extra-hepatic clearance.1
Teriparatide is rapidly eliminated with a decrease to non-quantifiable concentrations within 3 hours of the dose.1
Enclosed Prescribing Information
FORTEO® (teriparatide [rDNA origin] injection), Lilly
Reference
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.
2. Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485-492. http://dx.doi.org/10.1007/s00223-010-9424-6
Date of Last Review: November 11, 2019